Baseline donor and recipient characteristics stratified by weekday and weekend transplantation
| Weekday Tx (N=99 061) | Weekend Tx (N=37 654) | p Value | |
|---|---|---|---|
| Recipient characteristics | |||
| Age (mean±SD) | 49.6±13.2 | 49.6±13.2 | 0.71* |
| Gender (% males) | 60.6 | 60.6 | 0.87† |
| Race (%) | 0.16† | ||
| White | 52.0 | 52.3 | |
| Black | 30.4 | 30.5 | |
| Hispanic | 12.7 | 12.2 | |
| Other | 5.0 | 5.0 | |
| BMI median (IQR) | 25.2 (22.0–29.2) | 25.1 (22.0–29.3) | 0.30‡ |
| Diagnosis of ESRD | 0.29† | ||
| Diabetes | 22.9 | 22.9 | |
| Hypertension | 24.3 | 24.4 | |
| Glomerulonephritis | 23.7 | 24.0 | |
| Cystic kidney disease | 8.8 | 8.9 | |
| Other | 18.5 | 18.0 | |
| Unknown | 1.8 | 1.8 | |
| Days on waiting list, median (IQR) | 559 (228–1069) | 565 (229–1067) | 0.28‡ |
| Peak level of PRA (%) median, (75, 90, 95 centiles) | 2 (16, 78, 93) | 1 (15, 77, 93) | 0.33‡ |
| Prior kidney Tx (%) | 10.6 | 10.3 | 0.119† |
| Cold ischaemia time in hours: median (IQR) | 19 (13–24) | 18 (13–24) | <0.001‡ |
| Zero HLA mismatch (%) | 14.2 | 13.5 | 0.002† |
| Number of HLA mismatches (mean±SD) | 3.5±1.9 | 3.5±1.8 | 0.056* |
| ABO-incompatible Tx | 5.1 | 4.7 | 0.027† |
| Year of transplantation (%) | 0.072§ | ||
| 1994 (April 1)-1995 (n=17 816) | 9.2 | 9.5 | |
| 1996–2000 (n=57, 880) | 27.3 | 27.7 | |
| 2001–2005 (n=71, 353) | 30.5 | 30.0 | |
| 2006–2010 (September 3) (n=72 615) | 32.9 | 32.8 | |
| Donor characteristics | |||
| Age (mean±SD) | 37.3±17.1 | 37.3±17.1 | 0.52* |
| Gender (% males) | 59.6 | 58.7 | 0.003† |
| BMI median (IQR) | 25.2 (22.0–29.2) | 25.1 (22.0–29.3) | 0.30‡ |
| Race | <0.001† | ||
| White | 73.9 | 74.0 | |
| Black | 11.8 | 12.4 | |
| Hispanic | 12.3 | 11.6 | |
| Other | 2.0 | 1.9 | |
| Expanded criteria donor % | 16.4 | 16.4 | 0.89† |
| Donor creatinine mg/dL (mean±SD) | 1.15±1.30 | 1.14±1.33 | 0.70† |
*t-test independent samples.
†χ2-test proportions.
‡Mann-Whitney test.
§χ2-trend test.
BMI, body mass index; ESRD, end-stage renal disease; HLA, human leucocyte antigen; PRA, panel reactive antibodies; Tx, transplant.